Nia Adeniji
@sadebecks
Followers
215
Following
857
Statuses
292
Fellow (PGY3) Hematology Oncology @UCSF Previous: @StanfordMed | @MIT | @genentech Interests : Oncology , health equity , Tumor Microenvironment
San Francisco, CA
Joined May 2013
Thrilled to finally share our recent paper in Nature Cancer which characterizes the tumor immune microenvironment of microscopic residual HCC and identifies drivers of tumor recurrence!! So thankful to have been mentored by @renumathyd and thankful for the whole team 🎉🎉🎉🎉🎉🎉
1/7 Excited to see our paper out now in @NatureCancer, please read and share! We combined spatial analysis of clinical samples and transgenic mouse models of #HCC to determine the mechanism of persistence of residual disease and suggest a therapeutic approach to improve outcomes. I will explain the key findings in a few tweets, the full paper is online- A short blog summarizing the key findings-
1
1
16
RT @AnaVManana: #ASCOLung Practice changing LAURA study of osimertinib post-chemoradiation in EGFR mut unresectable NSCLC #ASCO24 #LCSM…
0
13
0
Lastly, adjuvant nivo after CROSS for those who do NOT achieve pCR may bridge or even surpass the efficacy gap seen in CROSS in the ESOPEC trial. -OS data from Checkmate 577 is still pending but PFS data is encouraging. ✨ #ASCO24 #Medscapefellows
0
0
0
Notable result: CROSS may be better for those who are older 🧓🏿 and have node negative disease #ASCO24
0
0
0
But per Dr Goodman's detailed followup, there were some differences in the performance of CROSS in ESOPEC vs prev. CROSS trial that we must consider.. - fewer pts completed pre-op tx -fewer pts achieved pCR (time to sx is shorter!!) -mOS much shorter #ASCO24
#Medscapefellows
0
0
0
RT @AnaVManana: Love sharing last night with our wonderful group of trainees & mentees, international collaborators, and @UCSFCancer facul…
0
15
0
ADCs continue to be 🔥 in the oncologic therapeutic landscape. We now need to consider payload resistance in addn to others when deciding on next lines of therapy after progression on an ADC (re Dr Patricia LoRusso) #ASCO24 #Medscapefellows
0
0
0
Multimodal AI can risk stratify breast cancer patients for distant metastasis using histopathological images +/- clinical data ( re Dr Daniel Kates-Harbeck) #ASCO24 #Medscapefellows
0
0
0
Dr Jane Perlmutter just gave an interesting talk on the pt perspectives in AI. In general, pts feel that AI will make things better: from reducing medical errors to better inclusion in studies. However, the ethical concerns are real & should be addressed #ASCO24 #Medscapefellows
0
0
0
Dr James Zhou (Stanford) starts the day off by talking about how prodictive and generative AI models are being used to transform cancer care. The future is bright! 🔆🔆 #ASCO24 #medsapefellows
0
0
0
Dr Ingr Svane: 👏🏿 great talk on the stunning response rates inpatients who received ODO+ PDL1 Vaccine w/ anti-PD1 in melanoma --> showed promising vaccine specific immunity based on neoantigens that are TME specific 🤩 --> randomized data TBD #ASCO24
0
0
0
0
0
1
Did you know that advanced glycation end-products (AGEs) produced in Type 2 diabetes affects liver viscoelasticity and promotes HCC growth?! Such cool work! So proud to be a part of it! 🎉 Congratulations to Dr. @TorokNatalie and collaborators on this accomplishment! #HCC #ECM
0
0
3
Thanks for the share @jlouissaint89 ! We are hoping that people find this work useful for their clinical practice.
✅ out this 💥 Review from @HepCommJournal‼️ 📑 Learn about current and emerging tools for #HCC surveillance🔎! 🧵 #LiverTwitter #OncTwitter #OpenAccess
1
2
10
This is the line at O'Hare last night for United Airlines passengers whose flights have been cancelled 😱😱 #happyweekendofthe4th @CNN @united
1
3
4
🤣🤣🤣🤣
I came for the leukocytosis but I stay for the DRAMA 👏
0
0
0
Awesome work by my mentor and fellow collaborators!
Thanks @HEP_Journal for invitation to write review "Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision making" 💪🤟with @HoshidaYujin! We discuss 🟢Genomic and immune heterogeneity 🟢Personalization of HCC treatment
0
0
1